By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


H. Lundbeck A/S 

Ottiliavej 9

Valby  Copenhagen  DK-2500  Denmark
Phone: 45-3630-1311 Fax: 45 3630 1940



Forest  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.

Company News
Agilis Biotherapeutics Names Former H. Lundbeck A/S (LUN.CO) Executive, Christopher J. Silber, MD, As Chief Medical Officer 1/25/2016 7:32:12 AM
H. Lundbeck A/S (LUN.CO) Release: Largest Prospective Study Evaluating The Effect Of Vigabatrin On Vision 11/25/2015 10:38:49 AM
H. Lundbeck A/S (LUN.CO): Experts Call For Urgent Action To Better Diagnose Severe Form Of Bipolar I Disorder, Which Is Costing Healthcare Economies Billions1,2 8/31/2015 11:04:38 AM
H. Lundbeck A/S (LUN.CO) Slashing 1,000 Employees as Company Faces Declining Revenue Due to Generic Competition 8/19/2015 5:53:09 AM
H. Lundbeck A/S (LUN.CO) Joins Innovative Alzheimer’s Disease Research Initiative 8/7/2015 11:02:08 AM
Otsuka Pharma, H. Lundbeck A/S (LUN.CO) Beat Competitors With FDA Approval of Schizophrenia Drug 7/13/2015 6:38:10 AM
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015 7:40:06 AM
H. Lundbeck A/S (LUN.CO) And Ovid Technologies Announce Exclusive Worldwide Licensing Agreement For Gaboxadol 4/16/2015 11:04:40 AM
H. Lundbeck A/S (LUN.CO) And ‘Keep Memory Alive’ Invest To Support Multiple System Atrophy Research And Global Taskforce 4/14/2015 10:22:51 AM
H. Lundbeck A/S (LUN.CO) To Research Link Between Immune System And Brain Diseases 12/22/2014 10:59:54 AM